Atossa Therapeutics, Inc. (ATOS) vs Aytu BioPharma, Inc. (AYTU)
A side-by-side comparison of Atossa Therapeutics, Inc. and Aytu BioPharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ATOS
Atossa Therapeutics, Inc.
$2.45HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
AYTU
Aytu BioPharma, Inc.
$2.04HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — ATOS vs AYTU
growth of $100 · dividends reinvested · last 10yATOS -99.3% (-39.4%/yr)AYTU -100.0% (-68.9%/yr)ATOS compounded faster over this window
Log scale — wide-divergence pair
ATOS AYTU
ATOS vs AYTU: by the numbers
- •ATOS is the larger company ($24M vs $22M market cap).
- •Both run net losses; ATOS's is the smaller (0.00% vs -24.76% net margin).
Metrics side by side
Valuation
| Metric | ATOS | AYTU |
|---|---|---|
| P/S ratio | N/A | 0.38 |
| P/B ratio | 0.91 | 0.62 |
| FCF yield | N/A | 14.85% |
Profitability
| Metric | ATOS | AYTU |
|---|---|---|
| Gross margin | 0.00% | 63.95% |
| Operating margin | 0.00% | -14.44% |
| Net margin | 0.00% | -24.76% |
| ROE | -140.55% | -40.40% |
| ROIC | -146.30% | -14.21% |
Growth (annualized)
| Metric | ATOS | AYTU |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -2.59% |
| Total return CAGR (5Y) | -44.50% | -48.14% |
Frequently asked
- How have ATOS and AYTU total returns compared?
- Over the past 10 years, ATOS delivered -39.47% and AYTU delivered -68.87% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Atossa Therapeutics ROEAytu BioPharma ROEAtossa Therapeutics operating marginAytu BioPharma operating marginAtossa Therapeutics revenue growthAytu BioPharma revenue growthAtossa Therapeutics free cash flowAytu BioPharma free cash flow
Atossa Therapeutics & Aytu BioPharma appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.